Allosteric activation of the 5-HT_3AB receptor by mCPBG by Miles, Timothy F. et al.
Allosteric Activation of the 5-HT3AB Receptor by mCPBG✩
Timothy F. Milesa, Henry A. Lestera, and Dennis A. Doughertyb,*
aDivision of Biology and Biological Engineering, California Institute of Technology, 1200 E 
California Blvd, Pasadena, CA 91125, USA
bDivision of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E 
California Blvd, Pasadena, CA 91125, USA
Abstract
The 5-HT3AB receptor contains three A and two B subunits in an A-A-B-A-B order. However, 
serotonin function at the 5-HT3AB receptor has been shown to depend solely on the A-A interface 
present in the homomeric receptor. Using mutations at sites on both the primary (E122) and 
complementary (Y146) faces of the B subunit, we demonstrate that meta-chlorophenyl biguanide 
(mCPBG), a 5-HT3 selective agonist, is capable of binding to and activating the 5-HT3AB 
receptor at all five subunit interfaces of the heteromer. Further, mCPBG is capable of allosterically 
modulating the activity of serotonin from these sites. While these five binding sites are similar 
enough that they form to a monophasic dose – response relationship, we uncover subtle 
differences in the heteromeric binding sites. We also find that the A-A interface appears to 
contribute disproportionately to the efficacy of 5-HT3AB receptor activation.
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1. INTRODUCTION
5-HT3 receptors are excitatory ligand-gated ion channels of the Cys-loop (pentameric) 
receptor super-family that also includes nicotinic acetylcholine (nAChR), glycine and 
GABAA receptors (Lummis, 2012). Members of the super-family share a common 
architecture and an agonist binding site that spans the interface between two subunits. In 
heteromeric pentamers, some interfaces can serve as allosteric modulatory sites, being 
unresponsive to the native agonist but responsive to small molecule allosteric modulators. 
The prototypical example of this is the allosteric action of benzodiazepines at GABAA 
receptors.
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The 5-HT3 family is principally composed of homomeric 5-HT3A receptors and heteromeric 
receptors containing some combination of the A subunit and either B, C, D, or E subunits 
(Davies et al., 1999; Maricq et al., 1991; Niesler et al., 2007). The best characterized 
heteromer is the 5-HT3AB receptor. In addition to contributing to the fundamental role of 
serotonin in the gut, the 5-HT3AB receptor is widely expressed in the brain and has been 
implicated in numerous salutary and pathological processes (Krzywkowski et al., 2008; 
Walstab et al., 2010).
The 5-HT3AB receptor contains three A and two B subunits (Miles et al., 2013). 
Fluorescence studies provide strong evidence that the most likely arrangement of the 
subunits is A-A-B-A-B (Miles et al., 2013; Thompson et al., 2011). Thus there are three 
potential types of binding sites in the 5-HT3AB receptor: the single A-A interface also found 
in the homomeric receptor (AA), the two heteromeric binding sites with the B subunit as the 
primary face (BA), and the two heteromeric binding sites with the B subunit as the 
complementary face (AB) (Figure 1). This potential complexity might afford one signaling 
molecule, serotonin (5-HT), the ability to elicit diverse responses depending on the 
repertoire of receptors present (Jensen et al., 2008). It also opens up the possible existence of 
allosteric modulatory sites as are seen in GABAA receptors.
Serotonin function at the 5-HT3AB receptor depends solely on the AA binding site present 
in the homomeric receptor (Lochner and Lummis, 2010; Michaelson et al., 2013; Thompson 
et al., 2011). Multiple studies have capitalized on the wealth of mutagenic data on 
homomeric receptors to identify crucial, non-conserved residues at both the principal and 
complementary faces of the B subunit that impact 5-HT function (Lochner and Lummis, 
2010; Michaelson et al., 2013). Combined, these studies demonstrate that only one serotonin 
molecule binds to and activates the 5-HT3AB receptor, a finding predicted by modeling of 
receptor kinetic parameters (Hapfelmeier et al., 2003). This makes the 5-HT3AB receptor 
unusual in the Cys-loop super-family, where multiple binding sites predominate.
m-chlorophenyl biguanide (mCPBG) is a 5-HT3 selective agonist (Kilpatrick et al., 1990). 
As described below, there is no detailed model for binding of mCPBG to the receptor. In the 
face of this relative paucity of binding information, it is not readily apparent that mCPBG 
should be incapable of acting at BA and AB binding sites. Indeed, a molecule has already 
been identified that is functional at AB binding sites (Thompson and Lummis, 2013; 
Thompson et al., 2012).
Here we demonstrate that, unlike serotonin, mCPBG is capable of binding to and activating 
the 5-HT3AB receptor at all five binding sites present in the heteromer. Through 
mutagenesis, we identify crucial residues on the B subunit corresponding to both principal 
and complementary faces, establishing that full activity is dependent on BA and AB sites. 
Further, we show that mCPBG is capable of allosterically modulating the activity of 
serotonin from BA binding sites, demonstrating the potential for future development of 5-
HT3AB ligands with benzodiazapine-like properties.
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2. METHODS
2.1 Mutagenesis and Preparation of cRNA and Oocytes
Mutant 5-HT3A and 5-HT3B receptor subunits, within the complete coding sequence for the 
human 5-HT3A and 5-HT3B receptor subunit (accession numbers P46098-1; NP_006019), 
were cloned into pGEMhe. Mutagenesis reactions were performed using the QuikChange 
mutagenesis kit (Stratagene), and confirmed by DNA sequencing. Harvested stage V-VI 
Xenopus oocytes were washed in four changes of Ca2+-free OR2 buffer (82.5 mM NaCl, 2 
mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.5), de-folliculated in 1 mg/ml collagenase for 
approximately 1 h, washed again in four changes of Ca2+-free OR2 and transferred to ND96 
(96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.5) 
supplemented with 0.28 mg/ml pyruvate, 0.05 mg/ml gentamicin and 0.12 mg/ml 
theophylline. Oocytes were injected with 5–25 ng mRNA produced by in vitro transcription 
using the mMESSAGE MACHINE kit (Ambion, Austin, Texas, USA) from cDNA 
subcloned into pGEMhe as previously described (Nowak et al., 1998). Electrophysiological 
measurements were performed after incubation for 24–72 h post-injection at 18° C.
Forward primers used for mutagenesis are listed below (Reverse primers are the reverse 
complement of the sequence shown):
5-HT3A E124Q: 5’-CGGACATTCTCAATCAGTTCGTGGATGTGGGGAAG-3’
5-HT3A Y148A: 5’-GGCGAAGTTCAGAACGCCAAGCCCCTTCAGGTGG-3’
5-HT3B E122Q: 5’-CGATATCATCATCAATCAGTTTGTGGACATTGAAAG-3’
5-HT3B E122A: 5’-CGATATCATCAATGCGTTTGTGGACATTGAAAG-3’
5-HT3B Y146A: 5’-CTGGGACCATTGAGAACGCTAAGCCCATCCAGGTGG-3’
2.2 Characterization of mutant receptors
Agonist-induced currents were recorded at 22–25° C from individual oocytes using the 
OpusXpress system (Molecular Devices Axon Instruments, Union City, CA). 5-HT, and m-
chlorophenylbiguanide (mCPBG) (Sigma) were stored as 25 mM aliquots at −20° C, diluted 
in Ca2+-free ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2,, 5 mM HEPES, pH 7.5) 
and delivered to cells via the automated perfusion system of the OpusXpress. Glass 
microelectrodes were backfilled with 3 M KCl and had a resistance of ~1 MΩ. The holding 
potential was −60 mV. Agonist doses in Ca2+-free ND96 were applied for 15 s followed by 
a 116 s wash with the running buffer. Dose-response data were obtained for ≥ 8 agonist 
concentrations on ≥ 5 cells. For 5-HT, dose concentrations ranged from 0.1 µM to 1 mM. 
For mCPBG, dose concentrations ranged from 0.1 µM to 50 µM. To determine EC50 values, 
concentration-response data were fitted to the four-parameter logistic equation, I = Imax/[1 + 
(EC50/[A])nH] where Imax is the maximal response plateau, [A] is the log concentration of 
agonist and nH is the Hill coefficient, using KaleidaGraph v3.6 software (Synergy Software, 
Reading, PA). Relative efficacies (ε ) of mCPBG, are reported as ε = Imax-mCPBG/Imax-5-HT. 
Efficacy was calculated for individual cells and then averaged and reported as mean ± 
S.E.M. Statistics were calculated by an unpaired, two-tailed students t test with significance 
ascribed to p-values < 0.05.
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3. RESULTS & DISCUSSION
3.1 5-HT and mCPBG behave differently at wild type 5-HT3AB receptors
While 5-HT and mCPBG certainly bind in the same interfacial binding pocket of the 
receptor, the detailed binding interactions involved are not identical. The amine of 5-HT 
forms a cation-π interaction at W178 (loop B, Figure 3) (Beene et al., 2002), and its 
hydroxyl forms a hydrogen bond at E124 (loop A) (Price et al., 2008). However, a 
comparably detailed binding model of mCPBG has not been enumerated. While mCPBG 
forms no interaction at W178, it does rely upon E124 for the initiation of channel gating 
(Miles et al., 2012).
Serotonin activates 5-HT3A receptors with a 3.4 µM EC50 and a relatively high Hill 
coefficient (nH), indicating a high level of cooperativity (Table 1). Though it need not be the 
case, this measure of cooperativity has tracked with the level of ligand binding in other Cys-
loop receptors (Mazzaferro et al., 2011; Tavares Xda et al., 2012). At the heteromeric AB 
receptor, both the EC50 and Hill coefficient markedly change, with a 7 fold decrease in 
ligand sensitivity (i.e., an increase in EC50) and a diminution of cooperativity reflected in a 
decreased Hill coefficient from 2.8 to 1.1 (Figure 2A; Table 1). These data are consistent 
with the finding that 5-HT likely acts at only the single AA binding site in the AB receptor.
mCPBG has a similar potency to 5-HT (3.8 µM) at the homomeric receptor along with a 
similarly high Hill coefficient (nH = 3.0) (Table 1). Unlike 5-HT however, both of these 
measures remain practically unchanged in the AB receptor (EC50 = 2.8 µM, nH = 2.5), 
(Figure 2B; Table 1) suggesting that mCPBG may retain the ability to bind the receptor at 
BA and AB binding sites. Meanwhile the efficacy relative to serotonin (ε ) of mCPBG 
surges from 0.85 to 2.75, as it transitions from a strong partial agonist to a super-agonist 
(Figure 2C; Table 1). This is consistent with a drop in the absolute efficacy of 5-HT due to 
its reduction to a single binding site in the heteromeric receptor.
3.2 The 5-HT3B subunit contributes to mCPBG activation of the 5-HT3AB receptor
E124 of loop A on the principal side of the 5-HT3A binding site plays a critical role in 
mCPBG activation (Figure 3). Mutation of E124 to glutamine has been shown to selectively 
ablate the ability of mCPBG to activate the 5-HT3A receptor, converting mCPBG to a 
competitive antagonist (Miles et al., 2012). However we find that the E124Q mutation in the 
A subunit of the heteromeric receptor, while highly deleterious, does not eliminate the 
ability of mCPBG to activate the 5-HT3AB receptor. Relative efficacy drops sharply to 0.36 
(Table 4) and the Hill coefficient falls from 3.0 to 1.0 (Table 3), suggesting the elimination 
of functional ligand binding sites. As the mutation disrupts AA and AB binding sites, this 
remaining activation suggests that mCPBG acts at BA binding sites.
To determine if this difference in response between the A and AB receptors was due to 
ligand binding at BA binding sites or to allosteric effects of the B subunit on the AA binding 
site, an experiment in which both agonists were applied was devised. First, an Imax dose of 
5-HT was applied to AB receptors bearing the E124Q mutation in the A subunit. After 5-HT 
maximally opened the channel and saturated its binding sites, mCPBG was co-applied at its 
EC50. Upon mCPBG addition, a second wave of receptor opening corresponding to an 
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additional 60 percent beyond the 5-HT Imax was observed (ΔImax = +60 ± 9 %, n = 18) 
(Figure 4A). This result indicates that mCPBG binds allosterically, increasing 5-HT 
efficacy. When the same experiment is performed with an Imax concentration of mCPBG, 
upon co-application the current sharply declines to approximately the relative efficacy of 
mCPBG alone (ΔImax = −72 ± 2 %, n = 20) (Figure 4B). This is consistent with mCPBG 
displacement of 5-HT at the AA binding site at higher concentrations.
3.3 mCPBG binds to all five interfaces of the 5-HT3AB receptor
Given the ability of mCPBG to compete at the orthosteric AA binding site, it was presumed 
that allosteric binding occurs at the equivalent location on B subunit-containing BA and/or 
AB binding sites. To determine if the B subunit could functionally contribute to the 
principal, complementary or both faces of the potential binding site, mutants found to 
disrupt function in A subunits were introduced at the corresponding sites in the B subunit. 
E122Q (equivalent to E124 in the A subunit) was chosen for the principal face to probe BA 
binding sites.
Fewer crucial ligand interactions to the complementary face that could probe AB binding are 
known (Van Arnam and Dougherty, 2014). Previous studies demonstrated that Y148 on 
loop E of the A subunit is critical for both serotonin binding and gating of the homomeric 
receptor (Beene et al., 2004) (Figure 3). Mutation of Y148 to alanine also results in a loss of 
function for mCPBG in the homopentamer, though less than that observed for 5-HT (Tables 
2 and 3). The relative efficacy of mCPBG increases over 4 fold (Table 4), suggesting that 
while this mutation affects mCPBG, it is more deleterious for serotonin function. 5-HT3AB 
receptors bearing Y148A in the A subunits show a similar pattern of effects. However as 
serotonin is oblivious to mutation of the B subunit (Table 2), the comparable mutation in the 
B subunit should probe only whether mCPBG acts at AB binding sites.
5-HT3AB receptors containing mutations that disrupt BA or AB binding sites were then 
assessed with both 5-HT and mCPBG. While mCPBG EC50 remains unchanged for both 
mutant receptors, relative efficacy is significantly affected. mCPBG remains a super-agonist 
of slightly lower efficacy, 1.94 for E122Q (BA disrupted) and 2.18 for Y146A (AB 
disrupted) (Figure 5 and Table 4). The lack of effect on mCPBG EC50 is expected if the 
mutations completely disrupt the binding sites that contain them while mCPBG is capable of 
opening the receptor, though less effectively, through the unaffected binding sites that 
remain. It is also possible that the apparent agonist efficacy at the receptor is decreased 
because the fraction of the response corresponding to the disrupted binding sites is shifted 
outside the observable window for mCPBG. This would not take an enormous loss of 
function, as mCPBG appears to be a quite effective open channel blocker at concentrations 
above 100 µM (Hapfelmeier et al., 2003).
The decrease in relative efficacy for the two mutations (E122Q and Y146A) indicates that 
the B subunit is capable of functionally contributing via both BA and AB binding sites. The 
similarity of the magnitude of the effect is consistent with the loss of two out of five possible 
binding sites in each case. As the number of remaining binding sites in either mutant 
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receptor would still outnumber that of serotonin (AA binding site only), it might be expected 
that mCPBG remains a super-agonist at the mutant receptors.
5-HT3AB receptors containing both B subunit mutations (both BA and AB disrupted) show 
a relative efficacy that is still further decreased to 1.58. (Figure 5 and Table 4). This is 
significantly (p < 0.05) different from both single mutants, demonstrating that the two 
mutations are additive, as expected given their actions at different binding site types. The 
double mutant still has a significantly higher relative efficacy for mCPBG than is seen at the 
homomeric receptor (ε = 0.85), where mCPBG also binds only AA sites. This suggests 
either that function is not completely disrupted at the BA or AB binding sites or that the 
presence of the B subunit allosterically improves the relative efficacy of mCPBG activation 
through the AA binding site. In either case, the disruption of all four B subunit-containing 
binding sites (BA and AB) is nearly an order of magnitude less deleterious than the 
disruption of both AA and AB binding sites. This suggests that the five binding sites do not 
contribute equally to mCPBG efficacy and that the AA binding site has a special 
importance.
3.4 Evidence for differences in heteromeric binding site organization
To test whether the mutations are, in fact, completely disrupting function at the binding sites 
that contain them, heteromeric receptors in which the critical glutamate in every subunit 
(E124 in the A subunits and E122 in the B subunits) is mutated to glutamine were probed 
(disrupting all five binding sites). Unexpectedly, this quintuple mutant receptor is still 
responsive to mCPBG, with a relative efficacy only slightly worse than that of receptors 
with the mutation in the A subunit alone (disrupting AA and AB) (Figure 6 and Table 4). 
Thus it appears that there are subtle differences in the B-containing binding sites of the 
heteromeric receptor.
The more drastic alanine mutation at E124 shows different effects. 5-HT3AB receptors with 
E122A in the B subunits (disrupting AA and AB binding sites) again showed no change in 
mCPBG EC50 but a large decrease in relative efficacy to 1.60, slightly worse than that for 
E122Q (ε = 1.94) (Figure 6 and Tables 3 and 4). Heteromeric receptors bearing E124Q in 
the A subunits and E122A in the B subunits (disrupting all five binding sites) now show the 
expected destruction of mCPBG agonist activity (ε < 0.01), akin to E124Q mutation in the 
homomeric 5-HT3A receptor (Figure 5 and Table 4).
It appears that the AB binding site also behaves slightly differently with regard to mutation 
of E124. It would be expected based on the homomeric receptor that E124Q would destroy 
both the AA and AB binding sites. If so, the addition of Y146A in the B subunits (also 
disrupting AB) should have no additional effect. This is not the case however, as relative 
efficacy decreases from 0.36 to 0.18, suggesting that E124Q in the A subunit is not 
completely destroying the AB binding sites (Figure 6 and Table 4).
3.5 Conclusions
Unlike serotonin, which is only capable of activating 5-HT3AB through its AA interface, 
mCPBG is capable of binding the receptor at all five subunit interfaces. Mutation of E124 
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(TyrA) of loop A and Y146 of Loop E on the B subunit show that mCPBG acts on both BA 
and AB binding sites. Importantly, we find that mCPBG is capable of allosterically 
modulating the serotonin response through its binding at these additional interfaces. These 
findings highlight the potential for the development of allosteric modulators of heteromeric 
5-HT3 receptors, akin to the benzodiazepine actions at GABAA receptors.
ACKNOWLEDGEMENTS
We would like to thank Dr. Sarah Lummis (Cambridge) and Dr. Noah Duffy for helpful discussion.
ABBREVIATIONS
5-HT serotonin
5-HT3 serotonin type 3 receptor
mCPBG meta-chlorophenyl biguanide
nH Hill coefficient
REFERENCES
1. Beene DL, Brandt GS, Zhong W, Zacharias NM, Lester HA, Dougherty DA. Cation-p interactions 
in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the 
anomalous binding properties of nicotine. Biochemistry. 2002; 41:10262–10269. [PubMed: 
12162741] 
2. Beene DL, Price KL, Lester HA, Dougherty DA, Lummis SC. Tyrosine residues that control 
binding and gating in the 5-hydroxytryptamine3 receptor revealed by unnatural amino acid 
mutagenesis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 
2004; 24:9097–9104. [PubMed: 15483128] 
3. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF. The 5-HT3B 
subunit is a major determinant of serotonin-receptor function. Nature. 1999; 397:359–363. 
[PubMed: 9950429] 
4. Hapfelmeier G, Tredt C, Haseneder R, Zieglgansberger W, Eisensamer B, Rupprecht R, Rammes G. 
Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 
receptor. Biophysical journal. 2003; 84:1720–1733. [PubMed: 12609874] 
5. Jensen AA, Davies PA, Brauner-Osborne H, Krzywkowski K. 3B but which 3B and that's just one 
of the questions: the heterogeneity of human 5-HT3 receptors. Trends in pharmacological sciences. 
2008; 29:437–444. [PubMed: 18597859] 
6. Kilpatrick GJ, Butler A, Burridge J, Oxford AW. 1-(m-chlorophenyl)-biguanide, a potent high 
affinity 5-HT3 receptor agonist. European journal of pharmacology. 1990; 182:193–197. [PubMed: 
2144822] 
7. Krzywkowski K, Davies PA, Feinberg-Zadek PL, Brauner-Osborne H, Jensen AA. High-frequency 
HTR3B variant associated with major depression dramatically augments the signaling of the human 
5-HT3AB receptor. Proceedings of the National Academy of Sciences of the United States of 
America. 2008; 105:722–727. [PubMed: 18184810] 
8. Lochner M, Lummis SC. Agonists and antagonists bind to an A-A interface in the heteromeric 5-
HT3AB receptor. Biophysical journal. 2010; 98:1494–1502. [PubMed: 20409468] 
9. Lummis SC. 5-HT(3) receptors. The Journal of biological chemistry. 2012; 287:40239–40245. 
[PubMed: 23038271] 
10. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional 
expression of the 5HT3 receptor, a serotonin-gated ion channel. Science. 1991; 254:432–437. 
[PubMed: 1718042] 
Miles et al. Page 7
Neuropharmacology. Author manuscript; available in PMC 2016 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
11. Mazzaferro S, Benallegue N, Carbone A, Gasparri F, Vijayan R, Biggin PC, Moroni M, Bermudez 
I. Additional acetylcholine (ACh) binding site at alpha4/alpha4 interface of (alpha4beta2)2alpha4 
nicotinic receptor influences agonist sensitivity. The Journal of biological chemistry. 2011; 
286:31043–31054. [PubMed: 21757735] 
12. Michaelson SD, Paulsen IM, Kozuska JL, Martin IL, Dunn SM. Importance of recognition loops B 
and D in the activation of human 5-HT(3) receptors by 5-HT and meta-chlorophenylbiguanide. 
Neuropharmacology. 2013; 73:398–403. [PubMed: 23810831] 
13. Miles TF, Bower KS, Lester HA, Dougherty DA. A coupled array of noncovalent interactions 
impacts the function of the 5-HT3A serotonin receptor in an agonist-specific way. ACS chemical 
neuroscience. 2012; 3:753–760. [PubMed: 23077719] 
14. Miles TF, Dougherty DA, Lester HA. The 5-HT3AB receptor shows an A3B2 stoichiometry at the 
plasma membrane. Biophysical journal. 2013; 105:887–898. [PubMed: 23972841] 
15. Niesler B, Walstab J, Combrink S, Moller D, Kapeller J, Rietdorf J, Bonisch H, Gothert M, 
Rappold G, Bruss M. Characterization of the novel human serotonin receptor subunits 5-HT3C,5-
HT3D, and 5-HT3E. Molecular pharmacology. 2007; 72:8–17. [PubMed: 17392525] 
16. Nowak, MW.; Gallivan, JP.; Silverman, SK.; Labarca, CG.; Dougherty, DA.; Lester, HA.; Conn, 
PM. Methods in Enzymology. Academic Press; 1998. In vivo incorporation of unnatural amino 
acids into ion channels in Xenopus oocyte expression system; p. 504-529.
17. Price KL, Bower KS, Thompson AJ, Lester HA, Dougherty DA, Lummis SC. A hydrogen bond in 
loop A is critical for the binding and function of the 5-HT3 receptor. Biochemistry. 2008; 
47:6370–6377. [PubMed: 18498149] 
18. Tavares X, da S, Blum AP, Nakamura DT, Puskar NL, Shanata JA, Lester HA, Dougherty DA. 
Variations in binding among several agonists at two stoichiometries of the neuronal, alpha4beta2 
nicotinic receptor. Journal of the American Chemical Society. 2012; 134:11474–11480. [PubMed: 
22716019] 
19. Thompson AJ, Lummis SC. Discriminating between 5-HT A and 5-HT AB receptors. British 
journal of pharmacology. 2013
20. Thompson AJ, Price KL, Lummis SC. Cysteine modification reveals which subunits form the 
ligand binding site in human heteromeric 5-HT3AB receptors. The Journal of physiology. 2011; 
589:4243–4257. [PubMed: 21708905] 
21. Thompson AJ, Verheij MH, de Esch IJ, Lummis SC. VUF10166, a novel compound with differing 
activities at 5-HT(3)A and 5-HT(3)AB receptors. The Journal of pharmacology and experimental 
therapeutics. 2012; 341:350–359. [PubMed: 22306960] 
22. Van Arnam EB, Dougherty DA. Functional Probes of Drug-Receptor Interactions Implicated by 
Structural Studies: Cys-Loop Receptors Provide a Fertile Testing Ground. Journal of medicinal 
chemistry. 2014
23. Walstab J, Rappold G, Niesler B. 5-HT(3) receptors: role in disease and target of drugs. 
Pharmacology & therapeutics. 2010; 128:146–169. [PubMed: 20621123] 
Miles et al. Page 8
Neuropharmacology. Author manuscript; available in PMC 2016 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
HIGHLIGHTS
- Unlike 5-HT, mCPBG binds at heteromeric interfaces of the 5-HT3AB 
receptor.
- mCPBG is capable of allosterically modulating serotonin response.
- Heteromeric binding sites subtly differ from the homomeric site.
- The homomeric binding site contributes disproportionately to receptor 
activation.
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Figure 1. 
Top-down view of 5-HT3AB receptor based on GluCl crystal structure (PDB: 3RHW); 
interfacial agonist binding sites move in a counterclockwise direction from the principal to 
the complementary face. Three types of binding sites are present in the heteromeric receptor: 
AA, A subunit as both principal and complementary faces, BA, B subunit as principal and A 
subunit as complementary, and AB, A subunit as principal and B subunit as complementary. 
Serotonin binds only at AA interfaces, whereas mCPBG is capable of accessing all three 
types of binding site.
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Figure 2. 
5-HT and mCPBG dose-response data for wild type 5-HT3A and 5-HT3AB receptors. A. 5-
HT dose-response data for wild type 5-HT3A and 5-HT3AB receptors with current 
normalized to the maximum elicited 5-HT current. B. mCPBG dose-response data for wild 
type 5-HT3A and 5-HT3AB receptors with current normalized to the maximum elicited 
mCPBG current. C. mCPBG dose-response data for wild type 5-HT3A and 5-HT3AB 
receptors with current normalized to the maximum elicited 5-HT current. 5-HT3A data are 
shown in red and 5-HT3AB data are shown in blue.
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Figure 3. 
Model of the 5-HT3 receptor binding site. The principal subunit (left) contains three loops: 
A (orange), B (blue), and C (green). The complementary subunit (right) also contains three 
loops: D (red), E (purple), and F (yellow). The side chains of two conserved residues are 
shown: E124 of loop A and Y148 of loop E in the human 5-HT3A subunit (E122 and Y146 
in 5-HT3B). This image has been modified from the crystal structure of acetylcholine 
binding protein (AChBP) from Lymnaea stagnalis, (PDB code 1UW6) and is for illustrative 
purposes only.
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Figure 4. 
Dual agonist experiment on 5-HT3AB receptors bearing the E124Q mutation in the A 
subunit. A. Model of receptor binding by 5-HT and mCPBG and representative 
electrophysiology trace showing maximal 5-HT response followed by an additional 60 ± 9 
percent (n = 18) response upon addition of EC50 mCPBG. B. Model of receptor ligation by 
5-HT and mCPBG and representative electrophysiology trace showing maximal 5-HT 
response followed by a reduction in current by 72 ± 2 percent (n = 20) upon addition of 
saturating mCPBG, whereupon mCPBG outcompetes 5-HT for binding at the A-A interface.
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Figure 5. 
Relative efficacies of mCPBG at 5-HT3AB receptor mutants. All 5-HT3AB receptors 
bearing mutations in the B subunits are significantly different (p < 0.05, except AB Y146A p 
= 0.0501 from wild type) than both the wild type receptor and 5-HT3AB containing E124Q 
in the A subunit. 5-HT3AB bearing both E122Q and Y146A is significantly different (p < 
0.05) from both single mutants. Values are depicted as the mean ± standard error.
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Figure 6. 
Relative efficacies of mCPBG at 5-HT3AB receptors bearing mutations in both subunits. 
Addition of E122Q, E122A, or Y146A mutations to the B subunits show significant (p < 
0.05) reductions in relative efficacy. Values are depicted as the mean ± standard error.
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Table 4
5-HT3A and 5-HT3AB Receptor Relative Efficacies of mCPBG (ε). Values are reported as mean ± standard 
error. Wild type (WT). No subunit supplied (−). P-values calculated by an unpaired, two-tailed student’s t test 
analysis, with the mutant compared to the wild type receptor. Not determined (ND) as efficacy values were 
below detection limits.
A Subunit B Subunit ε # Cells P-value
WT - 0.85 ± 0.17 10 -
E124Q - < 0.01 10 ND
Y148A - 3.79 ± 0.37 7 < 0.0001
WT WT 2.75 ± 0.19 22 -
E124Q WT 0.36 ± 0.04 10 < 0.0001
Y148A WT 10.6 ± 0.9 14 < 0.0001
WT E122Q 1.94 ± 0.12 19 0.0013, < 0.0001a
WT E122A 1.60 ± 0.14 11 0.0004, < 0.0001a
WT Y146A 2.18 ± 0.17 13 0.0501, < 0.0001a
WT E122Q Y146A 1.58 ± 0.09 13 < 0.0001, < 0.0001a, 0.0355 b, 0.0047 c
E124Q E122Q 0.24 ± 0.02 13 < 0.0001, 0.0090 a
E124Q E122A < 0.01 8 ND
E124Q Y146A 0.18 ± 0.03 9 < 0.0001, 0.0025a
a
P-value for the mutant compared to A E124Q B wt.
b
P-value for the mutant compared to A wt B E122Q.
c
P-value for the mutant compared to A wt B Y146A.
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